Centered on CNS

A legacy of innovation, a portfolio of promise™




Deutsche Bank Healthcare Conference Jack Khattar – President & CEO May 2013 This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus' business strategy, goals and expectations concerning its product candidates, future operations, prospects, plans and objectives of management. The words "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. Supernus' operations involve risks and uncertainties, many of which are outside its control, and any one of which, or a combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Supernus assumes no obligation to update any forward-looking statements except as required by applicable law.

Supernus has filed with the U.S. Securities and Exchange Commission (SEC) reports and other documents required by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Before you purchase any Supernus securities, you should read such reports and other documents to obtain more complete information about the company's operations and business and the risks and uncertainties that it faces in implementing its business plan. You may get these documents for free by visiting EDGAR on the SEC website at <u>http://www.sec.gov</u>.



Commercial Stage CNS Pharma





23 Years of Successful Product Development Former Division of Shire

Oxtellar XR. upernus[®] Trokendi XR. (oxcarbazepine) extended-release tablets (topiramate) extended-release capsules **Shire** ONE DOSE DAIL Equetro. Carbatrol Carbatrol 10 mg, 20 mg, 30 mg CAPSULES lixed Salts of a Single-Entity Amphetamine Product) xtroamphetamine Sulfate Dextroamphetamine Saccharate GALDERMA Oracea (dowycycline, USP) ALLERCAN trospium chloride extended release cansul



Two Product Launches & Exciting Mid Stage Pipeline

Product	Indication	Development	NDA	Launch
Oxtellar XR™	Epilepsy			February 2013
Trokendi XR™	Epilepsy	Tentative FD	A Approval	3Q 2013
SPN-810	Impulsive Aggression in ADHD	Completed Phase IIb		
SPN-812	ADHD	Completed Phase IIa		
SPN-809	Depression	IND		



Strong Execution Since IPO in May 2012

Oxtellar XR™	Date of Achievement				
FDA Approval	October 2012				
Three Year Market Exclusivity	November 2012				
U.S. Launch	February 2013				
Trokendi XR™	Date of Achievement				
FDA Tentative Approval	June 2012				
Two U.S. Patents Issued	October 2012				
SPN-810	Date of Achievement				
Positive Phase IIb Data	November 2012				



Non-Compliance – A Serious Problem in Epilepsy

71% of patients report missing a dose at least once/month 45% reporting seizures after a missed dose

Serious Quality of Life Issues



Increased Healthcare Costs



Worsening of Condition


Non-compliance leads to breakthrough seizures

that cost annually in excess of \$26,000 per patient





Extended-Release AEDs = Significant Patient Benefits



Reduced Breakthrough Seizures & Reliable Seizure Control



Oxtellar XR[™]: Launched in February 2013

- The only once daily oxcarbazepine XR product in the U.S.
 - Adjunctive therapy in partial seizures in adults & children 6-17 years
 - Two U.S. patents issued with expiry no earlier than 2027
 - Three year market exclusivity granted

- Phase III trial established efficacy and safety
 - Multicenter, randomized in refractory partial onset epilepsy
 - 366 adult patients randomized to 1200mg, 2400mg or placebo
 - Significant improvement in tolerability profile across many AEs



Oxtellar XR™: Critical Improvement in AE Profile

55% Reduction in AE-Related Discontinuation vs. Trileptal®

Number (%) of Patients With:	Oxtellar XR 2400 mg/d (n=123)	Oxtellar XR 1200 mg/d (n=122)	Placebo (n=121)	
Any adverse event (AE)	85 (69)	69 (57)	67 (55)	
Treatment-related AEs	72 (58)	53 (43)	47 (39)	
AEs leading to discontinuation	37 (30)	20 (16)	15 (12)	


Discontinuations occurred on Trileptal® 2400 mg/d in **66.7%** of patients - Barcs G, et al study (*Epilepsia*. 2000;41[12]:1597-607).

% of Patients With:	Double Blind (16 weeks)	Open Label (1 year)		
	All Oxtellar XR (n=245)	All Oxtellar XR (n=214)		
AEs leading to discontinuation	23	5		



Oxtellar XR™: Can Enable Higher Dosing

Improved AE Profile at Double the Dose of Trileptal®





Based on comparison of Oxtellar XR Study 301 vs. Trileptal PI (adjunctive therapy study in adults); differences in trial design exist between the two studies. *Dizziness includes vertigo in Trileptal group.


Trokendi XR[™]: To Be Launched in 3Q 2013

- Received Tentative Approval in June 2012
 - Based on bioequivalence strategy
 - J&J data exclusivity expires June 22, 2013
 - Filed "Request for Final Approval" in December 2012
 - If approved before June 22nd, will be a tentative approval
- Final Approval and launch expected in 3Q 2013
- Two issued U.S. patents with expiry no earlier than 2027



Trokendi XR™: Switch Study to Establish Bioequivalence


Design mimics dose switching in actual clinical practice



- Multicenter, open-label, 3-period switch study
- Patients on other AEDs
- Trokendi XR[™] is bioequivalent to Topamax[®] at steady state



Overwhelming Patient Preference for Trokendi XR™





A Proven and Efficient Commercial Strategy

Targeting Conversion of IR Epilepsy Patients to our XR Products


- Relatively small population of neurologists
- Sales force of 75 reps building up to 100⁺ for two products
- Targeting top six deciles of prescribing physicians
- Synergy from overlap in physician audience between Oxtellar XR & Trokendi XR creating economies of scale

Senior Commercial Expertise

- Strong experience with key elements of commercial strategy:
 - Similar CNS products (Epilepsy & ADHD)
 - Switching from IR to XR



Trokendi XR™ & Oxtellar XR™ Target Significant Markets



(TRx's in millions)



Trokendi XR™ & Oxtellar XR™: A Significant Opportunity

Illustrative Example


Assumes Total Market of 10 MM Prescriptions (TRx) for Topiramate + Oxcarbazepine

Period Post Launch	Year 1		Year 2		Year 3		Year 4		Year 5	
Total Market (MM TRx)*	10.0		10.4		10.8		11.2		11.6	
Conversion Rate (%)		3	4	5	6	7	8	10	11	12
Potential Prescriptions (k) Trokendi XR + Oxtellar XR	100	300	416	520	648	756	896	1120	1276	1392
Example of Average Net \$/ Rx*	275	275	289	289	303	303	318	318	334	334
Potential Net Sales (\$MM)	27	82	120	150	196	229	285	356	426	465

* Assumes annual market growth of 4% and annual price increase of 5%




XR Products Perform Well When Effectively Promoted






Note: Year 3 for Lamictal XR is based on 3 months of data (Jul-Sep 2011).

Oxtellar XR™ Prescription Growth






Oxtellar XR™ Prescription Growth





Oxtellar XR™ Conversion Share Growth

Weekly Conversion Share %



Oxtellar XR launched in Feb 2013 (2.1 M addressable TRx market, WK), Carbatrol launched in April 1998 (7.6 M TRx market, IMS)



Oxtellar XR™ Key Launch Metrics

- Higher conversion share among:
 - Top ranking physicians approx 1%
 - Physicians called on 6 times or more since launch approx 2.5 3%
- Sales force focused on increasing call frequency
 - On average 600 calls per week in early weeks increased to 1300 calls in most recent week
- Qualitative research and reported patient cases showing:
 - High satisfaction with the product
 - Product is delivering on its differentiated profile
- To date, achieved managed care coverage for 135 million lives
 - Majority of patients not paying more than \$15 with co-pay card



SPN-810: Novel Product for Impulsive Aggression in ADHD



25% of children with ADHD have persistent conduct problems such as impulsive aggression

- Expected to be first product approved to treat this serious condition
 - Co-morbidity in ADHD, schizophrenia, autism and bipolar disorder
 - Molindone hydrochloride (D1&2, 5HT2A antagonist)
- Phase IIb in Impulsive Aggression (IA) in ADHD
 - Multicenter, placebo-controlled, randomized
 - ADHD children 6-12 yrs old with IA
 - N=118, three doses and placebo
 - Add-on to stimulant treatment
 - Established safety & tolerability
 - Established efficacy at low and medium doses



SPN-812: Novel Non-Stimulant for ADHD

- Expected to have a better side effect profile than current therapies
 - Norepinephrine reuptake inhibitor
 - NCE for U.S. market
- Positive Phase IIa trial showed:
 - Safety & tolerability in 52 adults
 - Efficacy with statistical significance vs. placebo*
- Developing extended-release product

ADHD affects 6% to 9% of all school-age children and 3% to 5% of all adults




Financial Position

- As of March 2013
 - Cash and marketable securities of \$69.9M
 - Venture debt of \$20.1M
- In May 2013, closed on a \$90M Convertible Senior Note
 - Retired venture debt
 - Net proceeds ~\$67M
- Expected 2013 annual cash burn of \$85M \$95M
 - Lower than prior guidance of \$95M \$105M, primarily due to retiring venture debt (11% coupon)
- Current cash sufficient to fund operations through end of 2014
 - Expect to be cash flow breakeven by then, based on revenue ramp of new products



Company Highlights



- Commercial stage CNS pharma with robust pipeline & 23 years of successful track record
- Strong execution since IPO
- Encouraging early launch metrics on Oxtellar XR
- Final approval & launch of Trokendi XR in 3Q 2013
- Continue to progress SPN-810 and SPN 812 in ADHD
- Cash position sufficient to cash flow breakeven

